Condition: Heart Failure · Sponsor: Colorado Prevention Center
Finerenone will be compared to placebo to determine efficacy and safety of treatment in patients with heart failure and reduced ejection fraction (HFrEF) who are intolerant or ineligible to receive treatment with steroidal mineralocorticoid receptor antagonists (sMRA).
This description comes directly from the study's public registry record.
Marc Bonaca · (303) 860-9900 · info@cpcmed.org
Always discuss trial participation with your own doctor first.
| FIN-10004 Fairhope, AL Investigational Site | Fairhope, Alabama, United States | Recruiting |
| Phoenix, AZ Investigative Site FIN-10115 | Phoenix, Arizona, United States | Recruiting |
| FIN-10401, Yuma, AZ | Yuma, Arizona, United States | Recruiting |
| Chula Vista, CA Investigative Site FIN-10419 | Chula Vista, California, United States | Recruiting |
| Chula Vista, CA Investigative Site FIN-10111 | Chula Vista, California, United States | Recruiting |
| FIN-10407, Northridge, CA | Northridge, California, United States | Recruiting |
| FIN-10412, Orange, CA | Orange, California, United States | Recruiting |
| FIN-10070, Pamona, CA | Pomona, California, United States | Recruiting |
| FIN-10024, Sacramento, CA | Sacramento, California, United States | Recruiting |
| FIN-10406, San Diego, CA | San Diego, California, United States | Recruiting |
| San Diego, CA Investigative Site FIN-10420 | San Diego, California, United States | Recruiting |
| FIN-10075 San Diego, CA Investigational Site | San Diego, California, United States | Recruiting |
+ 164 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06033950